Phase III trial of Daxas in COPD published in The Lancet-Takeda

Takeda Pharmaceutical has announced results of the REACT study demonstrating Daxas(roflumilast) significantly reduced exacerbations and hospitalizations in patients with severe chronic obstructive pulmonary disease (COPD), who are at risk of frequent and severe exacerbations despite already receiving inhalation therapy with ICS/LABA combinations or triple (LAMA/ICS/LABA) therapy. The study showed that roflumilast significantly reduced the rate of severe exacerbations by 24.3 percent and those requiring hospitalization by 23.9 percent, reducing the clinical and economic burden of this disease.

In patients receiving triple therapy, roflumilast significantly reduced the rate of severe exacerbations by 23.3 percent, indicating how patients with severe COPD may benefit most from the addition of roflumilast to their therapeutic regimen. These results have been published online in The Lancet.